ARS PHARMACEUTICALS, INC.
Ownership & governance
Executives 5Directors 10Avg age 59Avg tenure 6.5y
RL
Richard Lowenthal
Chief Executive Officer
Age 60Since 2018-08-31Profile →
+14
Executives5
Board of directors10
RL
Richard Lowenthal→
Director/Board Member
Age 60Since 2015-08-04
PS
Pratik Shah→
Chairman
Age 56Since 2022-11-07
RD
Rajeev Dadoo→
Director/Board Member
Age 55Since 2021-07-31
SI
Saqib Islam→
Director/Board Member
Age 56Since 2017-06-30
MK
Michael Kelly→
Director/Board Member
Age 60Since 2019-04-30
PK
Peter Kolchinsky→
Director/Board Member
Age 49Since 2021-07-31
BS
Brenton Saunders→
Director/Board Member
Age 56Since 2021-04-30
PS
Phillip Schneider→
Director/Board Member
Age 70Since 2019-04-30
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| RA Capital Management LP | 10.94 % | 10,860,977 |
| OrbiMed Advisors Private Equity | 8.347 % | 8,288,510 |
| Richard Lowenthal | 8.283 % | 8,225,473 |
| Rubric Capital Management LP | 8.056 % | 8,000,000 |
| Deerfield Management Co. LP (Private Equity) | 7.556 % | 7,503,812 |
Catalog · 2026-07-09
Registry officers15
| Name | Role | Since | Shares |
|---|---|---|---|
| Kathleen Scott | Director of Finance/CFO | 2022-01-31 | - |
| Peter Thompson | Chairman | 2016-03-31 | - |
| Pratik Shah | Chairman | 2022-11-07 | - |
| Richard Lowenthal | Chief Executive Officer | 2018-08-31 | - |
| Robert Bell | Chief Tech/Sci/R&D Officer | 2015-08-04 | - |
| Sarina Tanimoto | Chief Tech/Sci/R&D Officer | 2018-08-31 | - |
| Brenton Saunders | Director/Board Member | 2021-04-30 | - |
| Laura Shawver | Director/Board Member | 2022-11-07 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 22.5Range 15–30Analysts 4
15Mean 22.530
- Buy 4
Broker actions27
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Leerink Partners | Maintained | Outperform | 18 | 2026-08-13 |
| Leerink Partners | Maintained | Outperform | 24 | 2026-06-25 |
| Cantor Fitzgerald | Maintained | Overweight | 30 | 2026-05-28 |
| Roth Capital | Initiated | Buy | 40 | 2025-09-04 |
| Scotiabank | Initiated | Sector Outperform | 30 | 2025-03-07 |
| Raymond James | Maintained | Strong Buy | 28 | 2025-01-14 |
| Leerink Partners | Maintained | Outperform | 27 | 2025-01-13 |
| Cantor Fitzgerald | Reiterated | Overweight | 30 | 2024-10-08 |
| Leerink Partners | Maintained | Outperform | 25 | 2024-09-20 |
| Cantor Fitzgerald | Reiterated | Overweight | 30 | 2024-09-16 |
| Cantor Fitzgerald | Reiterated | Overweight | 30 | 2024-09-09 |
| Cantor Fitzgerald | Initiated | Overweight | 30 | 2024-08-20 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.